Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use.
